Loading…

Melatonin ameliorates cognitive deficits through improving mitophagy in a mouse model of Alzheimer’s disease

While melatonin is known to have protective effects in mitochondria‐related diseases, aging, and neurodegenerative disorders, there is poor understanding of the effects of melatonin treatment on mitophagy in Alzheimer's disease (AD). We used proteomic analysis to investigate the effects and und...

Full description

Saved in:
Bibliographic Details
Published in:Journal of pineal research 2021-12, Vol.71 (4), p.e12774-n/a
Main Authors: Chen, Chongyang, Yang, Chao, Wang, Jing, Huang, Xi, Yu, Haitao, Li, Shangming, Li, Shupeng, Zhang, Zaijun, Liu, Jianjun, Yang, Xifei, Liu, Gong‐Ping
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c3254-6cf0a42ca4e5a4ef998132263d504faa4b36243f5ec9b740017010e52fc2e3e3
cites cdi_FETCH-LOGICAL-c3254-6cf0a42ca4e5a4ef998132263d504faa4b36243f5ec9b740017010e52fc2e3e3
container_end_page n/a
container_issue 4
container_start_page e12774
container_title Journal of pineal research
container_volume 71
creator Chen, Chongyang
Yang, Chao
Wang, Jing
Huang, Xi
Yu, Haitao
Li, Shangming
Li, Shupeng
Zhang, Zaijun
Liu, Jianjun
Yang, Xifei
Liu, Gong‐Ping
description While melatonin is known to have protective effects in mitochondria‐related diseases, aging, and neurodegenerative disorders, there is poor understanding of the effects of melatonin treatment on mitophagy in Alzheimer's disease (AD). We used proteomic analysis to investigate the effects and underlying molecular mechanisms of oral melatonin treatment on mitophagy in the hippocampus of 4‐month‐old wild‐type mice versus age‐matched 5 × FAD mice, an animal model of AD. 5 × FAD mice showed disordered mitophagy and mitochondrial dysfunction as revealed by increased mtDNA, mitochondrial marker proteins and MDA production, decreased electron transport chain proteins and ATP levels, and co‐localization of Lamp1 and Tomm20. Melatonin treatment reversed the abnormal expression of proteins in the signaling pathway of lysosomes, pathologic phagocytosis of microglia, and mitochondrial energy metabolism. Moreover, melatonin restored mitophagy by improving mitophagosome–lysosome fusion via Mcoln1, and thus, ameliorated mitochondrial functions, attenuated Aβ pathology, and improved cognition. Concurrent treatment with chloroquine and melatonin blocked the positive behavioral and biochemical effects of administration with melatonin alone. Taken in concert, these results suggest that melatonin reduces AD‐related deficits in mitophagy such that the drug should be considered as a therapeutic candidate for the treatment of AD.
doi_str_mv 10.1111/jpi.12774
format article
fullrecord <record><control><sourceid>wiley_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1111_jpi_12774</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>JPI12774</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3254-6cf0a42ca4e5a4ef998132263d504faa4b36243f5ec9b740017010e52fc2e3e3</originalsourceid><addsrcrecordid>eNp1kLtOwzAUhi0EoqUw8ALIK0Na33Ibq4pLUREMHdgi1zlOXSVxZKdFZeI1eD2ehJQAG0c651--8w8fQpeUjGk3k01jxpTFsThCQxoREpA4fTlGQxILFnCSJgN05v2GEJIkSXSKBlxENOaMDlH9CKVsbW1qLCsojXWyBY-VLWrTmh3gHLRRpvW4XTu7LdbYVI2zO1MXuDKtbday2OPDN67s1kN3cyix1Xhavq3BVOA-3z88zo0H6eEcnWhZerj4yRFa3t4sZ_fB4uluPpsuAsVZKIJIaSIFU1JA2K1O04RyxiKeh0RoKcWKR0xwHYJKV7EghMaEEgiZVgw48BG67muVs9470FnjTCXdPqMkOyjLOmXZt7KOverZZruqIP8jfx11wKQHXk0J-_-bsofneV_5BfwjeMw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Melatonin ameliorates cognitive deficits through improving mitophagy in a mouse model of Alzheimer’s disease</title><source>Wiley-Blackwell Read &amp; Publish Collection</source><creator>Chen, Chongyang ; Yang, Chao ; Wang, Jing ; Huang, Xi ; Yu, Haitao ; Li, Shangming ; Li, Shupeng ; Zhang, Zaijun ; Liu, Jianjun ; Yang, Xifei ; Liu, Gong‐Ping</creator><creatorcontrib>Chen, Chongyang ; Yang, Chao ; Wang, Jing ; Huang, Xi ; Yu, Haitao ; Li, Shangming ; Li, Shupeng ; Zhang, Zaijun ; Liu, Jianjun ; Yang, Xifei ; Liu, Gong‐Ping</creatorcontrib><description>While melatonin is known to have protective effects in mitochondria‐related diseases, aging, and neurodegenerative disorders, there is poor understanding of the effects of melatonin treatment on mitophagy in Alzheimer's disease (AD). We used proteomic analysis to investigate the effects and underlying molecular mechanisms of oral melatonin treatment on mitophagy in the hippocampus of 4‐month‐old wild‐type mice versus age‐matched 5 × FAD mice, an animal model of AD. 5 × FAD mice showed disordered mitophagy and mitochondrial dysfunction as revealed by increased mtDNA, mitochondrial marker proteins and MDA production, decreased electron transport chain proteins and ATP levels, and co‐localization of Lamp1 and Tomm20. Melatonin treatment reversed the abnormal expression of proteins in the signaling pathway of lysosomes, pathologic phagocytosis of microglia, and mitochondrial energy metabolism. Moreover, melatonin restored mitophagy by improving mitophagosome–lysosome fusion via Mcoln1, and thus, ameliorated mitochondrial functions, attenuated Aβ pathology, and improved cognition. Concurrent treatment with chloroquine and melatonin blocked the positive behavioral and biochemical effects of administration with melatonin alone. Taken in concert, these results suggest that melatonin reduces AD‐related deficits in mitophagy such that the drug should be considered as a therapeutic candidate for the treatment of AD.</description><identifier>ISSN: 0742-3098</identifier><identifier>EISSN: 1600-079X</identifier><identifier>DOI: 10.1111/jpi.12774</identifier><identifier>PMID: 34617321</identifier><language>eng</language><publisher>England</publisher><subject>Alzheimer Disease - drug therapy ; Alzheimer's disease ; Amyloid beta-Protein Precursor - genetics ; Animals ; Cognition ; melatonin ; Melatonin - pharmacology ; Mice ; mitochondrial function ; Mitophagy ; proteomic ; Proteomics</subject><ispartof>Journal of pineal research, 2021-12, Vol.71 (4), p.e12774-n/a</ispartof><rights>2021 John Wiley &amp; Sons A/S. Published by John Wiley &amp; Sons Ltd</rights><rights>2021 John Wiley &amp; Sons A/S. Published by John Wiley &amp; Sons Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3254-6cf0a42ca4e5a4ef998132263d504faa4b36243f5ec9b740017010e52fc2e3e3</citedby><cites>FETCH-LOGICAL-c3254-6cf0a42ca4e5a4ef998132263d504faa4b36243f5ec9b740017010e52fc2e3e3</cites><orcidid>0000-0002-7807-374X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34617321$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chen, Chongyang</creatorcontrib><creatorcontrib>Yang, Chao</creatorcontrib><creatorcontrib>Wang, Jing</creatorcontrib><creatorcontrib>Huang, Xi</creatorcontrib><creatorcontrib>Yu, Haitao</creatorcontrib><creatorcontrib>Li, Shangming</creatorcontrib><creatorcontrib>Li, Shupeng</creatorcontrib><creatorcontrib>Zhang, Zaijun</creatorcontrib><creatorcontrib>Liu, Jianjun</creatorcontrib><creatorcontrib>Yang, Xifei</creatorcontrib><creatorcontrib>Liu, Gong‐Ping</creatorcontrib><title>Melatonin ameliorates cognitive deficits through improving mitophagy in a mouse model of Alzheimer’s disease</title><title>Journal of pineal research</title><addtitle>J Pineal Res</addtitle><description>While melatonin is known to have protective effects in mitochondria‐related diseases, aging, and neurodegenerative disorders, there is poor understanding of the effects of melatonin treatment on mitophagy in Alzheimer's disease (AD). We used proteomic analysis to investigate the effects and underlying molecular mechanisms of oral melatonin treatment on mitophagy in the hippocampus of 4‐month‐old wild‐type mice versus age‐matched 5 × FAD mice, an animal model of AD. 5 × FAD mice showed disordered mitophagy and mitochondrial dysfunction as revealed by increased mtDNA, mitochondrial marker proteins and MDA production, decreased electron transport chain proteins and ATP levels, and co‐localization of Lamp1 and Tomm20. Melatonin treatment reversed the abnormal expression of proteins in the signaling pathway of lysosomes, pathologic phagocytosis of microglia, and mitochondrial energy metabolism. Moreover, melatonin restored mitophagy by improving mitophagosome–lysosome fusion via Mcoln1, and thus, ameliorated mitochondrial functions, attenuated Aβ pathology, and improved cognition. Concurrent treatment with chloroquine and melatonin blocked the positive behavioral and biochemical effects of administration with melatonin alone. Taken in concert, these results suggest that melatonin reduces AD‐related deficits in mitophagy such that the drug should be considered as a therapeutic candidate for the treatment of AD.</description><subject>Alzheimer Disease - drug therapy</subject><subject>Alzheimer's disease</subject><subject>Amyloid beta-Protein Precursor - genetics</subject><subject>Animals</subject><subject>Cognition</subject><subject>melatonin</subject><subject>Melatonin - pharmacology</subject><subject>Mice</subject><subject>mitochondrial function</subject><subject>Mitophagy</subject><subject>proteomic</subject><subject>Proteomics</subject><issn>0742-3098</issn><issn>1600-079X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNp1kLtOwzAUhi0EoqUw8ALIK0Na33Ibq4pLUREMHdgi1zlOXSVxZKdFZeI1eD2ehJQAG0c651--8w8fQpeUjGk3k01jxpTFsThCQxoREpA4fTlGQxILFnCSJgN05v2GEJIkSXSKBlxENOaMDlH9CKVsbW1qLCsojXWyBY-VLWrTmh3gHLRRpvW4XTu7LdbYVI2zO1MXuDKtbday2OPDN67s1kN3cyix1Xhavq3BVOA-3z88zo0H6eEcnWhZerj4yRFa3t4sZ_fB4uluPpsuAsVZKIJIaSIFU1JA2K1O04RyxiKeh0RoKcWKR0xwHYJKV7EghMaEEgiZVgw48BG67muVs9470FnjTCXdPqMkOyjLOmXZt7KOverZZruqIP8jfx11wKQHXk0J-_-bsofneV_5BfwjeMw</recordid><startdate>202112</startdate><enddate>202112</enddate><creator>Chen, Chongyang</creator><creator>Yang, Chao</creator><creator>Wang, Jing</creator><creator>Huang, Xi</creator><creator>Yu, Haitao</creator><creator>Li, Shangming</creator><creator>Li, Shupeng</creator><creator>Zhang, Zaijun</creator><creator>Liu, Jianjun</creator><creator>Yang, Xifei</creator><creator>Liu, Gong‐Ping</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><orcidid>https://orcid.org/0000-0002-7807-374X</orcidid></search><sort><creationdate>202112</creationdate><title>Melatonin ameliorates cognitive deficits through improving mitophagy in a mouse model of Alzheimer’s disease</title><author>Chen, Chongyang ; Yang, Chao ; Wang, Jing ; Huang, Xi ; Yu, Haitao ; Li, Shangming ; Li, Shupeng ; Zhang, Zaijun ; Liu, Jianjun ; Yang, Xifei ; Liu, Gong‐Ping</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3254-6cf0a42ca4e5a4ef998132263d504faa4b36243f5ec9b740017010e52fc2e3e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Alzheimer Disease - drug therapy</topic><topic>Alzheimer's disease</topic><topic>Amyloid beta-Protein Precursor - genetics</topic><topic>Animals</topic><topic>Cognition</topic><topic>melatonin</topic><topic>Melatonin - pharmacology</topic><topic>Mice</topic><topic>mitochondrial function</topic><topic>Mitophagy</topic><topic>proteomic</topic><topic>Proteomics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chen, Chongyang</creatorcontrib><creatorcontrib>Yang, Chao</creatorcontrib><creatorcontrib>Wang, Jing</creatorcontrib><creatorcontrib>Huang, Xi</creatorcontrib><creatorcontrib>Yu, Haitao</creatorcontrib><creatorcontrib>Li, Shangming</creatorcontrib><creatorcontrib>Li, Shupeng</creatorcontrib><creatorcontrib>Zhang, Zaijun</creatorcontrib><creatorcontrib>Liu, Jianjun</creatorcontrib><creatorcontrib>Yang, Xifei</creatorcontrib><creatorcontrib>Liu, Gong‐Ping</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Journal of pineal research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chen, Chongyang</au><au>Yang, Chao</au><au>Wang, Jing</au><au>Huang, Xi</au><au>Yu, Haitao</au><au>Li, Shangming</au><au>Li, Shupeng</au><au>Zhang, Zaijun</au><au>Liu, Jianjun</au><au>Yang, Xifei</au><au>Liu, Gong‐Ping</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Melatonin ameliorates cognitive deficits through improving mitophagy in a mouse model of Alzheimer’s disease</atitle><jtitle>Journal of pineal research</jtitle><addtitle>J Pineal Res</addtitle><date>2021-12</date><risdate>2021</risdate><volume>71</volume><issue>4</issue><spage>e12774</spage><epage>n/a</epage><pages>e12774-n/a</pages><issn>0742-3098</issn><eissn>1600-079X</eissn><abstract>While melatonin is known to have protective effects in mitochondria‐related diseases, aging, and neurodegenerative disorders, there is poor understanding of the effects of melatonin treatment on mitophagy in Alzheimer's disease (AD). We used proteomic analysis to investigate the effects and underlying molecular mechanisms of oral melatonin treatment on mitophagy in the hippocampus of 4‐month‐old wild‐type mice versus age‐matched 5 × FAD mice, an animal model of AD. 5 × FAD mice showed disordered mitophagy and mitochondrial dysfunction as revealed by increased mtDNA, mitochondrial marker proteins and MDA production, decreased electron transport chain proteins and ATP levels, and co‐localization of Lamp1 and Tomm20. Melatonin treatment reversed the abnormal expression of proteins in the signaling pathway of lysosomes, pathologic phagocytosis of microglia, and mitochondrial energy metabolism. Moreover, melatonin restored mitophagy by improving mitophagosome–lysosome fusion via Mcoln1, and thus, ameliorated mitochondrial functions, attenuated Aβ pathology, and improved cognition. Concurrent treatment with chloroquine and melatonin blocked the positive behavioral and biochemical effects of administration with melatonin alone. Taken in concert, these results suggest that melatonin reduces AD‐related deficits in mitophagy such that the drug should be considered as a therapeutic candidate for the treatment of AD.</abstract><cop>England</cop><pmid>34617321</pmid><doi>10.1111/jpi.12774</doi><tpages>17</tpages><orcidid>https://orcid.org/0000-0002-7807-374X</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0742-3098
ispartof Journal of pineal research, 2021-12, Vol.71 (4), p.e12774-n/a
issn 0742-3098
1600-079X
language eng
recordid cdi_crossref_primary_10_1111_jpi_12774
source Wiley-Blackwell Read & Publish Collection
subjects Alzheimer Disease - drug therapy
Alzheimer's disease
Amyloid beta-Protein Precursor - genetics
Animals
Cognition
melatonin
Melatonin - pharmacology
Mice
mitochondrial function
Mitophagy
proteomic
Proteomics
title Melatonin ameliorates cognitive deficits through improving mitophagy in a mouse model of Alzheimer’s disease
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T05%3A55%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-wiley_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Melatonin%20ameliorates%20cognitive%20deficits%20through%20improving%20mitophagy%20in%20a%20mouse%20model%20of%20Alzheimer%E2%80%99s%20disease&rft.jtitle=Journal%20of%20pineal%20research&rft.au=Chen,%20Chongyang&rft.date=2021-12&rft.volume=71&rft.issue=4&rft.spage=e12774&rft.epage=n/a&rft.pages=e12774-n/a&rft.issn=0742-3098&rft.eissn=1600-079X&rft_id=info:doi/10.1111/jpi.12774&rft_dat=%3Cwiley_cross%3EJPI12774%3C/wiley_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3254-6cf0a42ca4e5a4ef998132263d504faa4b36243f5ec9b740017010e52fc2e3e3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/34617321&rfr_iscdi=true